Drug intelligence / Profile preview

streptokinase + streptodornase

Development stage
Phase 4
Lead developer
Hanmi Pharmaceutical
Modality
Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration
Topical, Intracavitary
01

Overview

A combination of two enzymes, streptokinase and streptodornase, both produced by hemolytic streptococci. This mixture is used primarily for its enzymatic debridement properties. It is applied topically to surface lesions or instilled in closed body cavities to remove clotted blood, fibrinous material, or purulent accumulations. The mechanism of action involves: - **Streptokinase** acts as a plasminogen activator, forming a complex with plasminogen that converts it into the active enzyme plasmin. Plasmin then degrades fibrin clots and other plasma proteins[1][4][3]. - **Streptodornase** is a deoxyribonuclease that liquefies pus by depolymerizing DNA in necrotic tissue. This combination facilitates the removal of dead tissue and exudates from wounds or body cavities but is not typically used systemically for thrombolysis like intravenous streptokinase alone[3].

Brand names
Distreptaza
Other names
Streptodornase and Streptokinase
02

Targets

PLG (Plasminogen)eDNA (Extracellular DNA)

Beyond the preview

Go deeper on streptokinase + streptodornase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on streptokinase + streptodornase.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call